ChromaDex banner
ChromaDex banner

Clinical trials

New Longevity supplement targets cognitive decline

Clinical trial planned for Mitocholine, which targets the “brain energy gap” to counteract development of metabolic syndrome and impede the onset of dementia. A London-based...

A year in Longevity: progress perspectives

2020's journey to extending healthy human Longevity. The journey to Longevity has many stages, whether it's a clinical pipeline, gaining regulatory approval for a drug,...

A year in Longevity: different perspectives

Looking for anti-aging solutions in some unusual places. 2020 has seen Longevity.Technology covering a variety of news in the Longevity sector, from discoveries in the...

A year in Longevity: founders’ perspectives

Speaking to the innovators behind some of Longevity’s most exciting companies. Continuing our look back at some of the highlights of 2020, we thought we’d...

A year in Longevity: science perspectives

Longevity leaders on the key issues facing our sector. Over the past year, we’ve had the pleasure of speaking to some of the Longevity sector’s...

Longevity biomarker firm to align CROs, pharma and consumers

Cerascreen expands from consumer biomarker testing into clinical trial recruitment and discovery of Longevity compounds. Combining a wide range of consumer biomarker testing kits with...

BioAge CEO: “It’s all about the data.”

BioAge's Kristen Fortney explains how focusing on human data will see two age-targeting drugs head to the clinic next year. Yesterday, the world again sat...

BioAge lands $90 million; gears up for clinical trials in 2021

Company also appoints Chief Medical Officer as it prepares to enter the clinic with two Phase 2-ready therapeutic compounds that target aging pathways. Longevity biotech...

Defining Alzheimer’s by biomarkers could improve clinical trials

Incorporating biomarkers into the research definition of Alzheimer's disease should lead to delayed progression, better treatment and new criteria for clinical trials. When we think...

Targeting inflammaging: the hidden “inflammapath” inside us

Keystone Bio seeks funding as it gears up for clinical trials of therapeutic targeting the “keystone pathogen” of chronic inflammaging. Lurking in the mouths of...

Let’s initiate trials of potential geroprotective therapies

Dr Lynne Cox explains the importance of geroprotectors – especially during COVID-19. This month The Lancet launches its own journal on Longevity, publishing clinically-focused Longevity and...

AgelessRx and funding an IRB-approved rapamycin trial

Rapamycin could be the PEARL in the Longevity oyster as new human trial seeks funding. AgelessRx is a platform that sells drugs and supplements including...

Big Brother approach to accelerate preclinical studies

Tracked.bio develops AI computer vision system that tracks flies and mice to reduce man-hours and increase data collected in Longevity studies. A Danish start-up aims...

ChromaDex releases results for NR study in C19 patients

Phase 2 study finds addition of a nutritional protocol into Covid-19 care pathway reduces recovery time to 6.6 days from 9.3 in mild-to-moderate patients. ChromaDex...

Using small data to target Alzheimer’s

NetraMark CEO on using AI to identify novel targets for treatment of Alzheimer’s disease. Despite the billions spent on research and development into treatments for...

Combining existing medicines to target aging

Rejuvenate Biomed closes in on €9 million funding round for human trials of sarcopenia-targeted combined drug. Already well-known for its beer and bureaucracy to its...

Longevity marketing and the need for clarity

Dr Oliver Zolman makes the case for Longevity companies adopting a checklist when it comes to making anti-aging claims. When it comes to marketing in...

New immune aging drug brings Longevity and C19 hope

Phase 2-ready drug can treat and reverse immune aging, BioAge claims. BioAge Labs' in-licensed clinical-stage therapy has potential for treating immune aging in older patients...

Longevity trials: time to change the approach?

Leading academic says high profile trial failures should drive changes in how we approach trials for drugs that target aging. Following the recent clinical trial...

Leading academic sees “great promise” in longevity supplements

Buck professor Brian Kennedy talks about AKG and the potential for supplements to deliver real anti-aging benefits. Following Tuesday’s news from the Buck Institute about...
ChromaDex TruNiagen
lumen

Latest articles